CAJ | 학술논문

目的：探讨氨磺必利对首发精神分裂症患者的临床疗效及糖脂代谢的影响。方法将70例首发精神分裂症患者随机分为两组，每组35例，研究组口服氨磺必利治疗，对照组口服利培酮治疗，观察8周。于治疗前后采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应，同时检测空腹血糖、总胆固醇、三酰甘油、血清胰岛素及体质量指数的变化。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前显著下降（P＜0．01）。治疗8周末研究组糖脂代谢各项指标检测结果与治疗前比较均无显著变化（P＞0．05），而对照组各项指标检测结果均较治疗前显著升高（P＜0．05或0．01），研究组各项指标检测结果均显著低于对照组（P＜0．05或 P＜0．01）；两组其他不良反应发生率比较差异无显著性（χ2＝0．32，P＞0．05）。结论氨磺必利治疗精神分裂症状患者疗效显著，对糖脂代谢影响较小。
목적：탐토안광필리대수발정신분렬증환자적림상료효급당지대사적영향。방법장70례수발정신분렬증환자수궤분위량조，매조35례，연구조구복안광필리치료，대조조구복리배동치료，관찰8주。우치료전후채용양성여음성증상량표평정림상료효，부반응량표평정불량반응，동시검측공복혈당、총담고순、삼선감유、혈청이도소급체질량지수적변화。결과치료후량조양성여음성증상량표총분급각인자분균교치료전현저하강（P＜0．01）。치료8주말연구조당지대사각항지표검측결과여치료전비교균무현저변화（P＞0．05），이대조조각항지표검측결과균교치료전현저승고（P＜0．05혹0．01），연구조각항지표검측결과균현저저우대조조（P＜0．05혹 P＜0．01）；량조기타불량반응발생솔비교차이무현저성（χ2＝0．32，P＞0．05）。결론안광필리치료정신분렬증상환자료효현저，대당지대사영향교소。
Objective Objective To explore the influence of amisulpride on clinical efficacy and glucolipid metabolism of first‐episode schizophrenia .Methods Seventy first‐episode schizophrenics were randomly divided into two groups of 35 ones each ,research group took orally amisulpride and control group did ris‐peridone for 8 weeks .Efficacies were assessed with the Positive And Negative Syndrome Scale (PANSS) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) , and changes of blood‐fasting sugar ,cholesterol total ,triacylglycerol ,serum insulin and body mass index (BMI) detected at the same time .Results After treatment the total and each factor scores of the PANSS of both groups significantly lowered compared with pretreatment (P<0 .05) .At the end of the 8th week there were no significant changes from pre‐ to post‐treatment in each index detection result of glucolipid metabolism in research group ( P> 0 .05) ,but those heightened more significantly after treatment com‐pared with pretreatment in control group (P<0 .05 or 0 .01);there were no significant group difference in incidences of other adverse reactions (χ2 =0 .32 ,P>0 .05) .Conclusion Amisulpride has an evident effect in schizophrenia and less influence on glucolipid metabolism .